Patent · US Active

Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof

US12187707B2 · kind B2 · utility

0Cited by

3References

13Claims

0Family size

Assignee

BETA PHARMA, INC. · US

Inventors

Michael N. Greco · Lansdale, US
Michael John Costanzo · Bonney Lake, US
Michael Alan Green · Easton, US
Jirong Peng · Mequon, US
Victoria Lynn Wilde · Montclair, US
Don Zhang · Princeton, US

Key dates

Filing date	Nov 12, 2021
Grant date	Jan 7, 2025
Priority date	—
Expiry date	Sep 15, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGER), such as various cancers, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.